Delivery Order SPE2DB24D2101-SPE2DB25FKLUW
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and requires completion by June 17, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $10,744.05 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes on November 4, 2025, with completion expected by November 5, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement supporting federal medical supply needs. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $19,792.71 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. This firm fixed price, competitively awarded contract was executed on September 10, 2025, with an ultimate completion date of September 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $11,411.43 under a firm fixed-price contract. The delivery order is non-set-aside and carries an ultimate completion date of September 4, 2025, with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a $27,454.56 delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract employs firm fixed price terms with an ultimate completion date of September 16, 2025, and utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Actemra 162 mg/0.9 mL syringes with a ceiling value of $8,326.33 under a firm fixed-price contract. This delivery order is non-set-aside and represents a child award under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $2,158.38 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX),...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order contract to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-competitive, firm fixed-price delivery order carries a ceiling value of $15,381.06 with an ultimate completion date of September 8, 2025. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB25FKLUWDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,877.84 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 mL syringes. The contract is a firm fixed price delivery order with an ultimate completion date of June 27, 2025, and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this order from its corporate office location. This delivery order is issued under the company's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's DLA contract vehicle enables delivery of a wide range of pharmaceutical products, medical supplies, specialty medications, brand-name and generic drugs, vaccines, and related medical commodities across multiple therapeutic domains. This specific delivery order for Actemra, a specialty biologic medication, exemplifies the company's role in supplying specialized pharmaceutical products to support military healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.9k | 6/26/25 |